Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doxorubicin microneedle array - SkinJect

Drug Profile

Doxorubicin microneedle array - SkinJect

Alternative Names: Doxorubicin-containing MNA - SkinJect; SkinJect™

Latest Information Update: 28 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SkinJect
  • Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Basal cell cancer

Most Recent Events

  • 28 Jul 2023 No recent reports of development identified for phase-I development in Basal-cell-cancer(First-line therapy, In the elderly, In adults) in USA (Transdermal, Patch)
  • 17 May 2022 University of Pittsburgh in collaboration with National Cancer Institute plans a phase Ib/II trial for Squamous cell cancer in USA (Transdermal) in June 2022 (NCT05377905)
  • 24 Sep 2021 SkinJect initiates a phase I trial for Basal cell cancer in USA (Transdermal) (NCT04928222)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top